CLOVES Syndrome : European Medicines Agency grants marketing authorisation for alpelisib
Aalpelisib has now been approved by the European Medicines Agency for the treatment of severe forms of PIK3CA-related overgrowth spectrum (PROS), including CLOVES syndrome. This therapeutic breakthrough is the result of the work carried out by Professor Guillaume Canaud and his team within the Translational Medicine and Targeted Therapies Unit at Université Paris Cité, Necker-Enfants Malades Hospital AP-HP, and Inserm.